Stemirna Therapeutics Company
Chinese news website Yicai.com reported February 10 that the mRNA vaccine being developed by Stermirna Therapeutics and Shanghai East Hospital of Tongji University had begun testing on animals, following approval on an urgent basis in January. Li Hangwen, CEO of Stermirna Therapeutics, told Xinhua in January that no more than 40 days will be needed to manufacture a vaccine sample.
Technology:
COVID
Industry:
Vaccine/Drug
Headquarters:
China
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership